- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Emcure Pharmaceuticals Limited — Board Meeting, 11-11-2025: Outcome of Board Meeting
11-11-2025 | 01:30 pm
11-11-2025 | 01:30 pm
Emcure Pharma's board approved strong Q2FY26 consolidated results: Revenue rose 13.4% to Rs 2,270 Cr, and PAT jumped 24.7% to Rs 251 Cr. The company also completed its Zuventus acquisition and partnered with Novo Nordisk for Poviztra®.
No comments yet. Be the first to comment!